Announcement on abnormal fluctuations in stock trading of Jinyao Pharmaceutical Co., Ltd.
Securities code: 600488 Securities abbreviation: Jinyao Pharmaceutical Number: 2026-028 Jinyao Pharmaceutical Co., Ltd.
Announcement on abnormal stock trading fluctuations
The company's board of directors and all directors guarantee that the contents of this announcement do not contain any false records, misleading statements or major omissions, and assume legal responsibility for the authenticity, accuracy and completeness of its contents.
Important content reminder:
The daily closing price increase deviation of the stock of Jinyao Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") on two consecutive trading days on May 11 and May 12, 2026 reached a cumulative 20%. According to the relevant provisions of the "Shanghai Stock Exchange Trading Rules", it is a case of abnormal stock trading fluctuations.
After the company’s self-examination and verification by written letters to the company’s controlling shareholder Tianjin Pharmaceutical Group Co., Ltd. (hereinafter referred to as the “Pharmaceutical Group”) and the indirect controlling shareholder Tianjin Hushen Biomedical Technology Co., Ltd. (hereinafter referred to as the “Jinhushen Pharmaceutical”), as of the disclosure date of this announcement, the company and the controlling shareholder have no major matters that should be disclosed but have not been disclosed.
The company's latest operating performance has declined significantly. In the first quarter of 2025, the company achieved operating income of 608 million yuan, a year-on-year decrease of 22.61%. The net profit attributable to shareholders of listed companies was 13.8913 million yuan, a year-on-year decrease of 76.07%. The net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 13.9675 million yuan, a year-on-year decrease of 75.64%. The company's main products are generic drugs, including steroid hormones, amino acid raw materials and preparations.
Investors are advised to pay attention to the risks of secondary market transactions, make rational decisions, and invest prudently.
1. Specific circumstances of abnormal stock trading fluctuations
The cumulative deviation of the daily closing price increase of the company's stock trading on two consecutive trading days on May 11 and May 12 reached 20%. According to the relevant provisions of the "Shanghai Stock Exchange Trading Rules", it is an abnormal fluctuation in stock trading.
2. Relevant situations that the company pays attention to and verifies
In accordance with the relevant regulations of the Shanghai Stock Exchange, the company conducted a self-examination on relevant matters and consulted the company’s controlling shareholder in writing for verification. The relevant situation is now explained as follows:
(1) Production and operation conditions
After the company's self-examination, the company's current production and operation activities are normal, and there have been no major changes in daily operations. There have been no major adjustments to the market environment or industry policies, there have been no significant fluctuations in production costs and sales, and the internal production and operation order is normal.
(2) Major events
After self-examination by the company and written inquiries from the controlling shareholder Pharmaceutical Group and the indirect controlling shareholder Tianjin, Shanghai and Shenzhen Pharmaceuticals, it has been verified that as of the disclosure date of this announcement, the company and the company's controlling shareholders do not have any major information that the company should disclose but has not disclosed; there are no major events involving the company that are in the planning stage, including but not limited to major asset restructuring, share issuance, major transaction matters, business restructuring, share repurchase, equity incentives, bankruptcy reorganization, major business cooperation, introduction of strategic investors and other major matters.
(3) Media reports, market rumors, and hot concepts
After verification by the company, the company has not found any media reports or market rumors or hot concept matters that may or have had an impact on the company's stock trading price.
(4) Other price-sensitive information
After the company's self-examination, the company found no other major events that may have a greater impact on the company's stock price. The company's directors, senior managers and controlling shareholders did not buy or sell the company's stocks during the period of abnormal fluctuations in the company's stock trading.
3. Related risk warnings
(1) Secondary market transaction risks
The cumulative deviation of the daily closing price increase in the company's stock trading on May 11 and May 12, 2026, for two consecutive trading days reached 20%, and the company's stock price rose significantly in the short term. Investors are kindly requested to pay attention to the risks of secondary market transactions, make rational decisions, and invest prudently.
(2) Business performance risks
The company's operating performance has declined significantly in the latest period. The company achieved operating income of 608 million yuan in the first quarter of 2025, a year-on-year decrease of 22.61%. The net profit attributable to shareholders of listed companies was 13.8913 million yuan, a year-on-year decrease of 76.07%. The net profit attributable to shareholders of listed companies after deducting non-recurring gains and losses was 13.9675 million yuan, a year-on-year decrease of 75.64%. The company's main products are generic drugs, including steroid hormones, amino acid raw materials and preparations.
(3) Other risks
The company solemnly reminds investors that the Shanghai Stock Exchange website (www.sse.com.cn), "China Securities News" and "Shanghai Securities News" are the company's designated information disclosure media. All information of the company is subject to the information published in the above designated media. Investors are kindly requested to invest rationally and pay attention to investment risks.
4. Statement of the Board of Directors and Commitments of Related Parties
The company's board of directors confirms that the company does not have any matters that should be disclosed in accordance with the "Shanghai Stock Exchange Stock Listing Rules" and other relevant regulations but has not been disclosed, or plans, negotiations, intentions, agreements, etc. related to these matters. The board of directors has also not been informed of the "Shanghai Stock Exchange Stock Listing Rules" and other relevant regulations that should be disclosed but have not been disclosed.
Announcement is hereby made.
Board of Directors of Jinyao Pharmaceutical Co., Ltd.
May 12, 2026